HilleVax is developing novel vaccines targeting norovirus, which is responsible for over 90% of epidemic non-bacterial gastroenteritis outbreaks and leads to approximately 200,000 deaths annually. The company's focus on vaccine commercialization aims to mitigate the significant global economic burden of norovirus, estimated at $60.3 billion each year.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Norovirus is the primary cause of epidemic non-bacterial gastroenteritis outbreaks, leading to significant morbidity and mortality worldwide. Current preventative measures are insufficient to curb the spread and impact of norovirus, which causes hundreds of millions of infections and substantial economic losses annually.
Solution
HilleVax is focused on developing and commercializing novel vaccines to prevent norovirus infections. Their vaccine candidates aim to address the unmet need for effective prophylaxis against this highly contagious virus. By targeting the underlying cause of norovirus gastroenteritis, HilleVax seeks to reduce the global burden of disease and associated economic costs. The company's efforts are directed towards mitigating the impact of norovirus outbreaks and improving public health outcomes through proactive immunization strategies.
Target Audience
The primary target audience includes individuals at risk of norovirus infection, public health organizations, and healthcare providers seeking preventative solutions.
Features
- Development of novel vaccine candidates against norovirus
- Focus on commercialization to ensure widespread availability